Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study.

Dubischar KL, Kadlecek V, Sablan B Jr, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, Mueller Z, Westritschnig K.

Pediatr Infect Dis J. 2017 Sep;36(9):889-897. doi: 10.1097/INF.0000000000001623.

PMID:
28441266
2.

Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.

Dubischar KL, Kadlecek V, Sablan JB, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, Kiermayr S, Spruth M, Westritschnig K.

Pediatr Infect Dis J. 2017 Sep;36(9):898-904. doi: 10.1097/INF.0000000000001615.

PMID:
28430748
3.

A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients.

Rello J, Krenn CG, Locker G, Pilger E, Madl C, Balica L, Dugernier T, Laterre PF, Spapen H, Depuydt P, Vincent JL, Bogár L, Szabó Z, Völgyes B, Máñez R, Cakar N, Ramazanoglu A, Topeli A, Mastruzzo MA, Jasovich A, Remolif CG, Del Carmen Soria L, Andresen Hernandez MA, Ruiz Balart C, Krémer I, Molnár Z, von Sonnenburg F, Lyons A, Joannidis M, Burgmann H, Welte T, Klingler A, Hochreiter R, Westritschnig K.

Crit Care. 2017 Feb 4;21(1):22. doi: 10.1186/s13054-017-1601-9.

4.

Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.

Cramer JP, Dubischar K, Eder S, Burchard GD, Jelinek T, Jilma B, Kollaritsch H, Reisinger E, Westritschnig K.

Vaccine. 2016 Aug 31;34(38):4579-4585. doi: 10.1016/j.vaccine.2016.07.029. Epub 2016 Jul 25.

PMID:
27460550
5.

Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.

Bézay N, Ayad A, Dubischar K, Firbas C, Hochreiter R, Kiermayr S, Kiss I, Pinl F, Jilma B, Westritschnig K.

Vaccine. 2016 May 17;34(23):2585-92. doi: 10.1016/j.vaccine.2016.03.098. Epub 2016 Apr 11.

PMID:
27079932
6.

Efficacy of a travelers' diarrhea vaccine system in travelers to India.

Steffen R, Cramer JP, Burchard G, Jelinek T, Schwarz U, Ramdas P, Chatterjee S, Jiang ZD, DuPont HL, Dewasthaly S, Westritschnig K, Behrens RH.

J Travel Med. 2013 Nov-Dec;20(6):374-9. doi: 10.1111/jtm.12064. Epub 2013 Aug 26.

7.

A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.

Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B.

Hum Vaccin Immunother. 2014;10(1):170-83. doi: 10.4161/hv.26565. Epub 2013 Sep 24.

8.

Antigen processing and presentation by dendritic cells is independent of coronin 1.

Westritschnig K, BoseDasgupta S, Tchang V, Siegmund K, Pieters J.

Mol Immunol. 2013 Apr;53(4):379-86. doi: 10.1016/j.molimm.2012.09.002. Epub 2012 Oct 23.

PMID:
23099476
9.

Staphylococcus aureus fibronectin-binding protein specifically binds IgE from patients with atopic dermatitis and requires antigen presentation for cellular immune responses.

Reginald K, Westritschnig K, Linhart B, Focke-Tejkl M, Jahn-Schmid B, Eckl-Dorna J, Heratizadeh A, Stöcklinger A, Balic N, Spitzauer S, Niederberger V, Werfel T, Thalhamer J, Weidinger S, Novak N, Ollert M, Hirschl AM, Valenta R.

J Allergy Clin Immunol. 2011 Jul;128(1):82-91.e8. doi: 10.1016/j.jaci.2011.02.034. Epub 2011 Apr 21.

PMID:
21513970
10.

Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.

Gadermaier E, Staikuniene J, Scheiblhofer S, Thalhamer J, Kundi M, Westritschnig K, Swoboda I, Flicker S, Valenta R.

Allergy. 2011 Sep;66(9):1174-82. doi: 10.1111/j.1398-9995.2011.02592.x. Epub 2011 Apr 11.

PMID:
21480924
11.

Immunoglobulin E antibody reactivity to bacterial antigens in atopic dermatitis patients.

Reginald K, Westritschnig K, Werfel T, Heratizadeh A, Novak N, Focke-Tejkl M, Hirschl AM, Leung DY, Elisyutina O, Fedenko E, Valenta R.

Clin Exp Allergy. 2011 Mar;41(3):357-69. doi: 10.1111/j.1365-2222.2010.03655.x. Epub 2010 Dec 14.

12.

A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1.

Edlmayr J, Niespodziana K, Linhart B, Focke-Tejkl M, Westritschnig K, Scheiblhofer S, Stoecklinger A, Kneidinger M, Valent P, Campana R, Thalhamer J, Popow-Kraupp T, Valenta R.

J Immunol. 2009 May 15;182(10):6298-306. doi: 10.4049/jimmunol.0713622.

13.

Different allergenic activity of grass pollen allergens revealed by skin testing.

Westritschnig K, Horak F, Swoboda I, Balic N, Spitzauer S, Kundi M, Fiebig H, Suck R, Cromwell O, Valenta R.

Eur J Clin Invest. 2008 Apr;38(4):260-7. doi: 10.1111/j.1365-2362.2008.01938.x.

PMID:
18339006
14.

Isolation, expression and immunological characterization of a calcium-binding protein from Parietaria pollen.

Bonura A, Gulino L, Trapani A, Di Felice G, Tinghino R, Amoroso S, Geraci D, Valenta R, Westritschnig K, Scala E, Mari A, Colombo P.

Mol Immunol. 2008 May;45(9):2465-73. doi: 10.1016/j.molimm.2008.01.009. Epub 2008 Mar 4.

PMID:
18289680
15.

Three-dimensional structure of the cross-reactive pollen allergen Che a 3: visualizing cross-reactivity on the molecular surfaces of weed, grass, and tree pollen allergens.

Verdino P, Barderas R, Villalba M, Westritschnig K, Valenta R, Rodriguez R, Keller W.

J Immunol. 2008 Feb 15;180(4):2313-21.

16.

Immunogold electron microscopic localization of the 2 EF-hand calcium-binding pollen allergen Phl p 7 and its homologues in pollens of grasses, weeds and trees.

Grote M, Westritschnig K, Valenta R.

Int Arch Allergy Immunol. 2008;146(2):113-21. doi: 10.1159/000113514. Epub 2008 Jan 18.

PMID:
18204277
17.

A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin.

Westritschnig K, Linhart B, Focke-Tejkl M, Pavkov T, Keller W, Ball T, Mari A, Hartl A, Stöcklinger A, Scheiblhofer S, Thalhamer J, Ferreira F, Vieths S, Vogel L, Böhm A, Valent P, Valenta R.

J Immunol. 2007 Dec 1;179(11):7624-34.

18.

Mast cell-derived proteases control allergic inflammation through cleavage of IgE.

Rauter I, Krauth MT, Westritschnig K, Horak F, Flicker S, Gieras A, Repa A, Balic N, Spitzauer S, Huss-Marp J, Brockow K, Darsow U, Behrendt H, Ring J, Kricek F, Valent P, Valenta R.

J Allergy Clin Immunol. 2008 Jan;121(1):197-202. Epub 2007 Sep 29.

PMID:
17904627
19.

Allergen cleavage by effector cell-derived proteases regulates allergic inflammation.

Rauter I, Krauth MT, Flicker S, Gieras A, Westritschnig K, Vrtala S, Balic N, Spitzauer S, Huss-Marp J, Brockow K, Darsow U, Ring J, Behrendt H, Semper H, Valent P, Valenta R.

FASEB J. 2006 May;20(7):967-9. Epub 2006 Apr 3.

PMID:
16585063
20.

A comparative analysis of the cross-reactivity in the polcalcin family including Syr v 3, a new member from lilac pollen.

Ledesma A, Barderas R, Westritschnig K, Quiralte J, Pascual CY, Valenta R, Villalba M, Rodríguez R.

Allergy. 2006 Apr;61(4):477-84.

PMID:
16512810
21.

Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7.

Westritschnig K, Focke M, Verdino P, Goessler W, Keller W, Twardosz A, Mari A, Horak F, Wiedermann U, Hartl A, Thalhamer J, Sperr WR, Valent P, Valenta R.

J Immunol. 2004 May 1;172(9):5684-92.

22.

Tree pollen allergens.

Mothes N, Westritschnig K, Valenta R.

Clin Allergy Immunol. 2004;18:165-84. No abstract available.

PMID:
15042915
23.

Immunotherapy of allergic disease.

Valenta R, Ball T, Focke M, Linhart B, Mothes N, Niederberger V, Spitzauer S, Swoboda I, Vrtala S, Westritschnig K, Kraft D.

Adv Immunol. 2004;82:105-53. Review. No abstract available.

PMID:
14975256
24.

Can we genetically engineer safer and more effective immunotherapy reagents?

Westritschnig K, Valenta R.

Curr Opin Allergy Clin Immunol. 2003 Dec;3(6):495-500. Review.

PMID:
14612675
25.

Identification of cross-reactive and genuine Parietaria judaica pollen allergens.

Stumvoll S, Westritschnig K, Lidholm J, Spitzauer S, Colombo P, Duro G, Kraft D, Geraci D, Valenta R.

J Allergy Clin Immunol. 2003 May;111(5):974-9.

PMID:
12743560
26.

Three-dimensional structure of the panallergen Phl p 7.

Verdino P, Westritschnig K, Valenta R, Keller W.

Int Arch Allergy Immunol. 2003 Jan;130(1):10-1. No abstract available.

PMID:
12576729
27.

Analysis of the sensitization profile towards allergens in central Africa.

Westritschnig K, Sibanda E, Thomas W, Auer H, Aspöck H, Pittner G, Vrtala S, Spitzauer S, Kraft D, Valenta R.

Clin Exp Allergy. 2003 Jan;33(1):22-7.

PMID:
12534545
28.

The cross-reactive calcium-binding pollen allergen, Phl p 7, reveals a novel dimer assembly.

Verdino P, Westritschnig K, Valenta R, Keller W.

EMBO J. 2002 Oct 1;21(19):5007-16.

29.

Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization.

Movérare R, Westritschnig K, Svensson M, Hayek B, Bende M, Pauli G, Sorva R, Haahtela T, Valenta R, Elfman L.

Int Arch Allergy Immunol. 2002 Aug;128(4):325-35.

PMID:
12218371
30.

Molecular, structural, and immunologic relationships between different families of recombinant calcium-binding pollen allergens.

Tinghino R, Twardosz A, Barletta B, Puggioni EM, Iacovacci P, Butteroni C, Afferni C, Mari A, Hayek B, Di Felice G, Focke M, Westritschnig K, Valenta R, Pini C.

J Allergy Clin Immunol. 2002 Feb;109(2):314-20.

PMID:
11842303

Supplemental Content

Loading ...
Support Center